PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
27.27%
Revenue growth above 1.5x META's 12.29%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
30.32%
Gross profit growth above 1.5x META's 12.33%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
80.61%
EBIT growth above 1.5x META's 10.27%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
80.61%
Operating income growth above 1.5x META's 16.44%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
136.94%
Net income growth above 1.5x META's 10.17%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
80.77%
EPS growth above 1.5x META's 10.47%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
76.92%
Diluted EPS growth above 1.5x META's 11.04%. David Dodd would see if there's a robust moat protecting these shareholder gains.
30.96%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
33.20%
Slight or no buyback while META is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
141.86%
OCF growth above 1.5x META's 6.39%. David Dodd would confirm a clear edge in underlying cash generation.
310.34%
Positive FCF growth while META is negative. John Neff would see a strong competitive edge in net cash generation.
895.18%
10Y revenue/share CAGR at 50-75% of META's 1223.16%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
895.18%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
895.18%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
412.93%
Below 50% of META's 2770.56%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
412.93%
5Y net income/share CAGR 1.25-1.5x META's 304.58%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
412.93%
3Y net income/share CAGR above 1.5x META's 194.47%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.13%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
No Data
No Data available this quarter, please select a different quarter.
23.88%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-6.01%
We have a declining book value while META shows 5.80%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-28.57%
We’re deleveraging while META stands at 0.08%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-58.80%
Our R&D shrinks while META invests at 6.52%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-100.00%
We cut SG&A while META invests at 12.01%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.